These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 31545446)

  • 1. CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer.
    Zhou Q; Xiong W; Zhou X; Gao RS; Lin QF; Liu HY; Li JN; Tian XF
    Mol Med Rep; 2019 Nov; 20(5):4244-4252. PubMed ID: 31545446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation.
    Wang C; Li Z; Shao F; Yang X; Feng X; Shi S; Gao Y; He J
    J Exp Clin Cancer Res; 2017 Jun; 36(1):84. PubMed ID: 28645305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of
    Uhercik M; Sanders AJ; Owen S; Davies EL; Sharma AK; Jiang WG; Mokbel K
    Anticancer Res; 2017 Aug; 37(8):4249-4254. PubMed ID: 28739716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.
    Yang K; Xu J; Liu Q; Li J; Xi Y
    Pathol Res Pract; 2019 Feb; 215(2):265-271. PubMed ID: 30466764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
    Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
    Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD1 distribution pattern, regardless of the cell origin, is an independent microenvironmental prognostic factor for progression-free survival in follicular lymphoma.
    Szumera-Ciećkiewicz A; Poleszczuk J; Kuczkiewicz-Siemion O; Paszkiewicz-Kozik E; Rymkiewicz G; Sokół K; Borysiuk A; Kotarska M; Kawecka M; Owczarek D; Pytlak B; Walewski J; Prochorec-Sobieszek M
    Pathol Res Pract; 2020 Oct; 216(10):153096. PubMed ID: 32853965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes.
    Sial N; Ahmad M; Hussain MS; Iqbal MJ; Hameed Y; Khan M; Abbas M; Asif R; Rehman JU; Atif M; Khan MR; Hameed Z; Saeed H; Tanveer R; Saeed S; Sharif A; Asif HM
    Sci Rep; 2021 Oct; 11(1):19873. PubMed ID: 34615943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed Cell Death Protein 1-PDL1 Interaction Prevents Heart Damage in Chronic
    Fonseca R; Salgado RM; Borges da Silva H; do Nascimento RS; D'Império-Lima MR; Alvarez JM
    Front Immunol; 2018; 9():997. PubMed ID: 29867974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
    Li CJ; Lin LT; Hou MF; Chu PY
    Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
    Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E
    Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
    Guo L; Bodo J; Durkin L; Hsi ED
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collagen Triple Helix Repeat Containing 1 Expression in Osteosarcoma: A New Predictor of Prognosis.
    Liu Y; Abulimiti N; Wang C
    Ann Clin Lab Sci; 2018 May; 48(3):338-344. PubMed ID: 29970438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
    Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
    BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis.
    Chen YL; Wang TH; Hsu HC; Yuan RH; Jeng YM
    PLoS One; 2013; 8(7):e70324. PubMed ID: 23922981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung.
    Igarashi T; Teramoto K; Ishida M; Hanaoka J; Daigo Y
    Oncol Rep; 2017 Oct; 38(4):2189-2196. PubMed ID: 28791392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
    Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
    Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.
    Tamura T; Ohira M; Tanaka H; Muguruma K; Toyokawa T; Kubo N; Sakurai K; Amano R; Kimura K; Shibutani M; Maeda K; Hirakawa K
    Anticancer Res; 2015 Oct; 35(10):5369-76. PubMed ID: 26408698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.